



The project entitled: *Creating an academia-based platform to discover substances acting on serotonergic or glutamatergic systems as potential new antidepressant or anxiolytic drugs* is supported by the grant PNRF-103-AI-1/07 from Norway through the Norwegian Financial Mechanism within the Polish-Norwegian Research Fund.

## PROJECT DETAILS:

The Project is carried out as a Consortium and involves three partners: the Institute of Pharmacology of the Polish Academy of Sciences in Kraków; the Institute of Medical Biology, the Faculty of Health Science of the University of Tromsø; and the National Medicines Institute in Warsaw.

## MAIN OBJECTIVE:

To create an academia-based platform for discovering new antidepressant and/or anxiolytic agents with a shorter onset of action and fewer adverse effects.

On the basis of the accumulated knowledge, experience and validated experimental methods developed by the above-mentioned scientific institutions, we have re-scaled the existing research capabilities to a multi-level screening platform which facilitates the process of antidepressant and anti-anxiety drug discovery. Using molecular modeling techniques, we perform a virtual screening of compound libraries on the basis of our own pharmacophores and receptor models. In order to examine a broad range of chemical structures, the compound acquisition system is being constantly developed. The therapeutic potential of both in-house and externally synthesized compounds is first evaluated *in vitro* and subsequently by *in vivo* tests.

## INVITATION TO PARTICIPATE IN THE SCREENING PROGRAM:

One of the keys to hit identification (potential new drugs) is the chemical diversity of evaluated compounds. To this end we have initiated an extensive screening program addressed to research institutes in Poland and Norway, in which we offer a free testing of compounds.



INSTITUTE OF PHARMACOLOGY  
POLISH ACADEMY OF SCIENCES  
KRAKÓW, POLAND



DEPARTMENT OF MEDICAL BIOLOGY  
UNIVERSITY OF TROMSØ, NORWAY



NATIONAL MEDICINES INSTITUTE  
WARSAW, POLAND

### PROJECT LEADER

**Prof. Andrzej Pilc**  
Institute of Pharmacology  
Polish Academy of Sciences  
Department of Neurobiology  
12 Smętna Street  
31-343 Kraków, Poland  
tel.: +4812 6623-284  
fax: +4812 6374-500  
e-mail: nfpilc@cyf-kr.edu.pl

### POLISH PARTNER

**Prof. Zdzisław Chilmonczyk**  
National Medicines Institute  
Department of Cell Biology  
30/34 Chełmska Street  
00-725 Warsaw, Poland  
tel.: +4822 851 43 69  
e-mail: chilmon@il.waw.pl

### NORWEGIAN PARTNER

**Prof. Ingebrigt Sylte**  
Medical Pharmacology  
and Toxicology  
Department of Medical Biology  
Faculty of Health Science  
University of Tromsø  
Breivika MH, N-9037 Tromsø, Norway  
tel.: +47 77644 705  
e-mail: ingebrigt.sylte@uit.no

### CONTACT PERSON

**Assoc. Prof. Andrzej Bojarski**  
Institute of Pharmacology  
Polish Academy of Sciences  
Department of Medicinal Chemistry  
12 Smętna Street  
31-343 Kraków, Poland  
tel.: +4812 6623 365  
fax: +4812 6374 500  
e-mail: bojarski@if-pan.krakow.pl




## INVITATION TO PARTICIPATE IN THE SCREENING PROGRAM

The screening program is directed to research institutions from Poland and Norway, and compounds will be tested free of charge.

In the Project we focus on two main molecular targets which are recognized as important in antidepressant/anxiolytic mechanism of action:

- *the serotonergic system – compounds with dual SERT/5-HT<sub>1A</sub> antagonistic activity, and ligands of 5-HT<sub>6</sub> and 5-HT<sub>7</sub> receptors;*
- *the glutamatergic system – in which we concentrate mainly on groups II and III of metabotropic glutamate receptors (mGluR).*



The chemical structures of the submitted compounds are considered as an intellectual property of a Participant and will be protected as stated in the *General Principles of Co-operation*, which can be downloaded from the Project's web-page.